Alyeska Investment Group’s Bioventus BVS Stock Holding History

Alyeska Investment Group’s Portfolio BVS Stock Details BVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-279,497	Closed	-$4.27M	–	731
2021 Q1	$4.27M	Buy	+279,497	New	+$3.98M	0.06%	354

Other funds holding BVS

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Nuance Investments Kansas City, Missouri $717M AUM 3.8% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Alyeska Investment Group's BVS Position: Q2 2021 in Review

Alyeska Investment Group sold out of Bioventus (BVS) in Q2 2021, closing a stake of 279,497 shares — an estimated $4.27M sold.

Alyeska Investment Group first reported a position in BVS in Q1 2021 and held it in 1 quarter. The position peaked at $4.27M in Q1 2021. 53 funds tracked by Wall St. Rank hold BVS as of Q2 2021.

Alyeska Investment Group reported no remaining Bioventus position as of Q2 2021 after selling out during the quarter.
Alyeska Investment Group sold 279,497 Bioventus shares in Q2 2021, an estimated $4.27M.
Alyeska Investment Group first reported a position in Bioventus in Q1 2021 and held it in 1 quarter.
Alyeska Investment Group's Bioventus position peaked at $4.27M in Q1 2021.
53 funds tracked by Wall St. Rank held Bioventus as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.